Roches glp 1gip drug hits phase 2 diabetes trial fueling best disease prediction

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 24 Sept, 12:07 UTC

A phase 2 trial of Roche’s dual GLP-1/GIP receptor agonist has hit its primary endpoints, painting the drug candidate as a potential treatment for people with type 2 diabetes and overweight or obesity.

science

Sources

• T2Roches glp 1gip drug hits phase 2 diabetes trial fueling best disease predictionFierce Biotech / Fierce Healthcare / MedCity / GEN24 Sept, 12:07